Total VoCV | 2.5th Percentile | 97.5th Percentile | |
Probabilistic sensitivity analysis | |||
All vaccines | US$5.2T | US$4.1T | US$6.2T |
% different from total VoCV | −21.3% | 21.2% | |
Pfizer-BioNTech | US$1.9T | US$1.5T | US$2.3T |
% different from total VoCV | −21.2% | 20.5% | |
One-way sensitivity analyses | |||
IHME lower bound infections | |||
All vaccines | US$4.1T | ||
% different from total VoCV | −20.6% | ||
Pfizer-BioNTech | US$1.5T | ||
% different from total VoCV | −20.1% | ||
IHME upper bound infections | |||
All vaccines | US$6.3T | ||
% different from total VoCV | 21.8% | ||
Pfizer-BioNTech | US$2.3T | ||
% different from total VoCV | 22.3% | ||
IHME unscaled deaths | |||
All vaccines | US$4.2T | ||
% different from total VoCV | −18.2% | ||
Pfizer-BioNTech | US$1.5T | ||
% different from total VoCV | −20.7% | ||
0% discount rate | |||
All vaccines | US$5.8T | ||
% different from total VoCV | 13.3% | ||
Pfizer-BioNTech | US$2.2T | ||
% different from total VoCV | 14.3% | ||
6% discount rate | |||
All vaccines | US$4.8T | ||
% different from total VoCV | −7.2% | ||
Pfizer-BioNTech | US$1.8T | ||
% different from total VoCV | −7.9% |
IHME, Institute for Health Metrics and Evaluation; T, trillion; VoCV, value of COVID-19 vaccination.